Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DH001 for Prevention of Doxorubicin-induced Cardiotoxicity
NCT06092606Phase 2Recruiting
- Sponsor
- Mengyang Pharmaceutical
- Start
- Apr 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DH001 in doxorubicin-induced cardiotoxicity (AIC) (3 arms), sponsored by Mengyang Pharmaceutical. Primary endpoint: The incidence of cardiac events. Started Apr 2023; status: recruiting.
02
Drugs
DH001
03
Conditions
doxorubicin-induced cardiotoxicity (AIC)
Beyond the preview
Go deeper on NCT06092606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06092606.